0000000000454671

AUTHOR

J. De Leon

showing 2 related works from this author

Tools for optimising pharmacotherapy in psychiatry (therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests): focus on antidep…

2021

Contains fulltext : 238693.pdf (Publisher’s version ) (Open Access) Objectives: More than 40 drugs are available to treat affective disorders. Individual selection of the optimal drug and dose is required to attain the highest possible efficacy and acceptable tolerability for every patient.Methods: This review, which includes more than 500 articles selected by 30 experts, combines relevant knowledge on studies investigating the pharmacokinetics, pharmacodynamics and pharmacogenetics of 33 antidepressant drugs and of 4 drugs approved for augmentation in cases of insufficient response to antidepressant monotherapy. Such studies typically measure drug concentrations in blood (i.e. therapeutic …

Drugmedicine.medical_specialtyprecision medicinetherapeutic drug monitoringmedia_common.quotation_subjectStress-related disorders Donders Center for Medical Neuroscience [Radboudumc 13]brain imagingNeuroimagingPsykiatri03 medical and health sciences0302 clinical medicinePharmacotherapyNeuroimagingmedicineHumansIntensive care medicineBiological Psychiatrypharmacogeneticsmedia_commonPsychiatrymedicine.diagnostic_testbusiness.industryAntidepressantsPrecision medicineAntidepressive Agents030227 psychiatryPsychiatry and Mental healthTherapeutic drug monitoringPharmacogeneticsAntidepressants; brain imaging; pharmacogenetics; precision medicine; therapeutic drug monitoring; Antidepressive Agents; Drug Monitoring; Humans; Neuroimaging; Pharmacogenetics; PsychiatryAntidepressants; brain imaging; precision medicine; pharmacogenetics; therapeutic drug monitoringDrug MonitoringbusinessPharmacogeneticsWorld Journal of Biological Psychiatry
researchProduct

Pharmacogenomics in psychiatry: from therapeutic drug monitoring to genomic medicine.

2013

Psychiatry is increasingly combining new pharmacogenomic findings with therapeutic drug monitoring (TDM) to improve the safety and efficacy of pharmacotherapy. However, a distinction should be made between “nice to know” and “need to know” pharmacogenomic data because many results are statistically significant in meta-analyses but are not clinically relevant due to their low effect sizes. Some examples will illustrate this integration.

medicine.medical_specialtyGenotypeAlternative medicineNicePharmacotherapyNeed to knowmedicineGenomic medicineAnimalsHumansPharmacology (medical)Precision MedicinePsychiatrycomputer.programming_languagePharmacologyPsychiatryPsychotropic Drugsmedicine.diagnostic_testbusiness.industryMental DisordersTherapeutic drug monitoringPharmacogeneticsPharmacogenomicsDrug MonitoringbusinesscomputerClinical pharmacology and therapeutics
researchProduct